<List><item><source>MED</source><extId>26451330</extId><pmcid>PMC4592530</pmcid><annotations><annotation><prefix>umomab (Study MT103-104; , </prefix><exact>NCT00274742</exact><postfix>) were used. </postfix><tags><tag><name>NCT00274742</name><uri>http://identifiers.org/clinicaltrials/NCT00274742</uri></tag></tags><id>http://europepmc.org/articles/PMC4592530#europepmc-073e0c0854a1374c3f97603c8a11da11</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>n study in NHL (Study MT103-104; , </prefix><exact>NCT00274742</exact><postfix>).16 </postfix><tags><tag><name>NCT00274742</name><uri>http://identifiers.org/clinicaltrials/NCT00274742</uri></tag></tags><id>http://europepmc.org/articles/PMC4592530#europepmc-b4944b9c32c609715e36941348c7c882</id><type>Accession Numbers</type><section>Results (http://purl.org/orb/Results)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>